Not Specified (Ophthalmology Program)
Diabetic Macular Edema
Clinical-stageActive
Key Facts
About Therini Bio
Therini Bio is a private, San Francisco-based biotech founded in 2019, advancing a novel therapeutic platform targeting fibrin-mediated neuroinflammation. The company has a clinical-stage pipeline aimed at large markets with high unmet need, such as Alzheimer's disease and diabetic macular edema. It is led by an experienced team with deep expertise in neurology, ophthalmology, and drug development, and is backed by a top-tier syndicate of life science investors.
View full company profileTherapeutic Areas
Other Diabetic Macular Edema Drugs
| Drug | Company | Phase |
|---|---|---|
| OHB-401 | Oak Hill Bio | Pre-clinical |
| EY-001 | EyeYon Medical | Phase 1 |
| TAK-648 | Thermo Fisher Scientific | Phase 2 |
| AXPAXLI (OTX-TKI) | Ocular Therapeutix | Phase 3 |
| BGE-102 | BioAge Labs | Phase 1b/2a |
| 4D-150 | 4D Molecular Therapeutics | Phase 3 |